The estimated Net Worth of Zami Aberman is at least $834 Thousand dollars as of 10 February 2022. Zami Aberman owns over 80,616 units of Pluri Inc stock worth over $91,756 and over the last 17 years Zami sold PSTI stock worth over $742,059.
Zami has made over 18 trades of the Pluri Inc stock since 2011, according to the Form 4 filled with the SEC. Most recently Zami bought 80,616 units of PSTI stock worth $145,109 on 10 February 2022.
The largest trade Zami's ever made was buying 80,616 units of Pluri Inc stock on 10 February 2022 worth over $145,109. On average, Zami trades about 13,166 units every 107 days since 2007. As of 10 February 2022 Zami still owns at least 91,756 units of Pluri Inc stock.
You can see the complete history of Zami Aberman stock trades at the bottom of the page.
Zami's mailing address filed with the SEC is MATAM PARK, BUILDING #5, , HAIFA, L3, 3508409.
Over the last 17 years, insiders at Pluri Inc have traded over $7,081,854 worth of Pluri Inc stock and bought 2,345,914 units worth $14,327,834 . The most active insiders traders include Wolf Capital Limited Part..., Zami Aberman, and Israel Ben Yoram. On average, Pluri Inc executives and independent directors trade stock every 64 days with the average trade being worth of $54,123. The most recent stock trade was executed by Zami Aberman on 10 February 2022, trading 80,616 units of PSTI stock currently worth $145,109.
Pluristem Therapeutics Inc. is a leading regenerative medicine company developing novel placenta-based cell therapy product candidates. The Company has reported robust clinical trial data in multiple indications for its patented PLX cell product candidates and is currently conducting late-stage clinical trials in several indications. PLX cell product candidates are believed to release a range of therapeutic proteins in response to inflammation, muscle trauma, hematological disorders and radiation damage. The cells are grown using the Company's proprietary three-dimensional expansion technology and can be administered to patients off- the-shelf, without tissue matching. Pluristem has a strong intellectual property position; a
Pluri Inc executives and other stock owners filed with the SEC include: